186 related articles for article (PubMed ID: 19221750)
1. Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers.
Izbicka E; Diaz A; Streeper R; Wick M; Campos D; Steffen R; Saunders M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):993-9. PubMed ID: 19221750
[TBL] [Abstract][Full Text] [Related]
2. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts.
Tedeschi PM; Kathari YK; Farooqi IN; Bertino JR
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1029-32. PubMed ID: 25205429
[TBL] [Abstract][Full Text] [Related]
3. Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.
Serova M; Bieche I; Sablin MP; Pronk GJ; Vidaud M; Cvitkovic E; Faivre S; Raymond E
Br J Cancer; 2011 Jan; 104(2):272-80. PubMed ID: 21179031
[TBL] [Abstract][Full Text] [Related]
4. The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.
Visentin M; Unal ES; Goldman ID
Cancer Chemother Pharmacol; 2014 May; 73(5):1055-62. PubMed ID: 24682532
[TBL] [Abstract][Full Text] [Related]
5. Molecular, biochemical, and cellular pharmacology of pemetrexed.
Goldman ID; Zhao R
Semin Oncol; 2002 Dec; 29(6 Suppl 18):3-17. PubMed ID: 12571805
[TBL] [Abstract][Full Text] [Related]
6. Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies.
Molina JR
IDrugs; 2008 Jul; 11(7):508-21. PubMed ID: 18600598
[TBL] [Abstract][Full Text] [Related]
7. Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias.
Norris RE; Adamson PC
Cancer Chemother Pharmacol; 2010 May; 65(6):1125-30. PubMed ID: 19784838
[TBL] [Abstract][Full Text] [Related]
8. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
9. Pralatrexate - from bench to bedside.
Zain JM; Marchi E
Drugs Today (Barc); 2010 Feb; 46(2):91-9. PubMed ID: 20393637
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate analogues. 26. Inhibition of dihydrofolate reductase and folylpolyglutamate synthetase activity and in vitro tumor cell growth by methotrexate and aminopterin analogues containing a basic amino acid side chain.
Rosowsky A; Freisheim JH; Moran RG; Solan VC; Bader H; Wright JE; Radike-Smith M
J Med Chem; 1986 May; 29(5):655-60. PubMed ID: 2871191
[TBL] [Abstract][Full Text] [Related]
11. Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells.
Cho RC; Cole PD; Sohn KJ; Gaisano G; Croxford R; Kamen BA; Kim YI
Mol Cancer Ther; 2007 Nov; 6(11):2909-20. PubMed ID: 18025275
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of sensitivity and natural resistance to antifolates in a methylcholanthrene-induced rat sarcoma.
Li WW; Lin JT; Schweitzer BI; Bertino JR
Mol Pharmacol; 1991 Nov; 40(5):854-8. PubMed ID: 1719370
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
14. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).
Shih C; Habeck LL; Mendelsohn LG; Chen VJ; Schultz RM
Adv Enzyme Regul; 1998; 38():135-52. PubMed ID: 9762351
[TBL] [Abstract][Full Text] [Related]
15. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
16. Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn LG; Shih C; Chen VJ; Habeck LL; Gates SB; Shackelford KA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):42-7. PubMed ID: 10598554
[TBL] [Abstract][Full Text] [Related]
17. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
[TBL] [Abstract][Full Text] [Related]
18. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamylation of the dihydrofolate reductase inhibitor gamma-methylene-10-deazaaminopterin is not essential for antitumor activity.
Cao S; Abraham A; Nair MG; Pati R; Galivan JH; Hausheer FH; Rustum YM
Clin Cancer Res; 1996 Apr; 2(4):707-12. PubMed ID: 9816221
[TBL] [Abstract][Full Text] [Related]
20. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
